{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:39:17Z","timestamp":1794580757216,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021069","name":"Indivior Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.neuropharm.2025.110546","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T11:07:56Z","timestamp":1749208076000},"page":"110546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Reversal of a synthetic opioid overdose: Insights from a validated translational model"],"prefix":"10.1016","volume":"278","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8345-5980","authenticated-orcid":false,"given":"Celine M.","family":"Laffont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Purohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6341-4933","authenticated-orcid":false,"given":"Amparo","family":"de la Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2646-815X","authenticated-orcid":false,"given":"Phil","family":"Skolnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110546_bib1","series-title":"Provisional Drug Overdose Death Counts","author":"Ahmad","year":"2025"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110546_bib2","first-page":"637","article-title":"Tolerance to opioid\u2010induced respiratory depression in chronic high\u2010dose opioid users: a model\u2010based comparison with opioid\u2010naive individuals","volume":"109","author":"Algera","year":"2021","journal-title":"Clin. pharmacol. drug dev."},{"key":"10.1016\/j.neuropharm.2025.110546_bib3","article-title":"Slow dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal at the \u03bc\u2010opioid receptor","author":"Alhosan","year":"2024","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110546_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.31264","article-title":"Naloxone use in novel potent opioid and fentanyl overdoses in emergency department patients","volume":"6","author":"Amaducci","year":"2023","journal-title":"JAMA Netw. Open."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110546_bib5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMra1202561","article-title":"Management of opioid analgesic overdose","volume":"367","author":"Boyer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110546_bib6","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1021\/acschemneuro.8b00174","article-title":"DARK classics in chemical neuroscience: fentanyl","volume":"9","author":"Burns","year":"2018","journal-title":"ACS Chem. Neurosci."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2025.110546_bib7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0379-0738(00)00204-8","article-title":"The neuropathology of heroin abuse","volume":"113","author":"B\u00fcttner","year":"2000","journal-title":"Forensic Sci. Int."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2025.110546_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejphar.2005.08.008","article-title":"[(3)H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists","volume":"520","author":"Cassel","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110546_bib9","series-title":"Data from: State Unintentional Drug Overdose Reporting System (SUDORS)","year":"2025"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110546_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0303403","article-title":"Innovation and adaptation: the rise of a fentanyl smoking culture in San Francisco","volume":"19","author":"Ciccarone","year":"2024","journal-title":"PLoS One."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110546_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cpdd.1312","article-title":"Pharmacokinetic properties of an FDA\u2010approved intranasal nalmefene formulation for the treatment of opioid overdose","volume":"13","author":"Crystal","year":"2024","journal-title":"Clinical. pharmacol. drug dev."},{"key":"10.1016\/j.neuropharm.2025.110546_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1346109","article-title":"Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids","volume":"12","author":"Dahan","year":"2024","journal-title":"Front. Public Health."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110546_bib13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1533-2500.2011.00491.x","article-title":"Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review","volume":"12","author":"Darwish","year":"2012","journal-title":"Pain Pract."},{"issue":"16","key":"10.1016\/j.neuropharm.2025.110546_bib14","first-page":"e836","article-title":"Opioid-associated out-of-hospital cardiac arrest: distinctive clinical features and implications for health care and public responses: a scientific statement from the American Heart Association","volume":"143","author":"Dezfulian","year":"2021","journal-title":"Circulation (New York, N. Y.)"},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110546_bib15","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/jcph.2421","article-title":"Reversal of opioid-induced respiratory depression in healthy volunteers: comparison of intranasal nalmefene and intranasal naloxone","volume":"64","author":"Ellison","year":"2024","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110546_bib16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bph.14860","article-title":"Fentanyl depression of respiration: comparison with heroin and morphine","volume":"177","author":"Hill","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110546_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.41063","article-title":"Fentanyl, heroin, methamphetamine, and cocaine analyte concentrations in urine drug testing specimens","volume":"7","author":"Huhn","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110546_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/00333549241263526","article-title":"Effects of States' methods for estimating nonfatal overdose, United States, 2021","volume":"140","author":"Johnson","year":"2025","journal-title":"Publ. Health Rep."},{"key":"10.1016\/j.neuropharm.2025.110546_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.neuropharm.2019.02.008","article-title":"Respiratory depression and brain hypoxia induced by opioid drugs: morphine, oxycodone, heroin, and fentanyl","volume":"151","author":"Kiyatkin","year":"2019","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110546_bib20","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/jcph.759","article-title":"Pharmacokinetic properties and human use characteristics of an FDA\u2010approved intranasal naloxone product for the treatment of opioid overdose","volume":"56","author":"Krieter","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110546_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1399803","article-title":"Comparison of intranasal naloxone and intranasal nalmefene in a translational model assessing the impact of synthetic opioid overdose on respiratory depression and cardiac arrest","volume":"15","author":"Laffont","year":"2024","journal-title":"Front. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110546_bib22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/ajcp\/aqx138","article-title":"Newly emerging drugs of abuse and their detection methods: an ACLPS critical review","volume":"149","author":"Liu","year":"2018","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110546_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75129-2","article-title":"Brain hypoxia and metabolic crisis are common in patients with acute brain injury despite a normal intracranial pressure","volume":"14","author":"Lund","year":"2024","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110546_bib24","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/cpt.2696","article-title":"Development of a translational model to assess the impact of opioid overdose and naloxone dosing on respiratory depression and cardiac arrest","volume":"112","author":"Mann","year":"2022","journal-title":"Clin. Pharmacol. Therapeut"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110546_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1365-2125.1998.00035.x","article-title":"Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery","volume":"46","author":"Mather","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110546_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/PAF.0000000000000787","article-title":"Proliferation of novel synthetic opioids in postmortem investigations after core-structure scheduling for fentanyl-related substances","volume":"43","author":"Papsun","year":"2022","journal-title":"Am. J. Forensic Med. Pathol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110546_bib28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.15585\/mmwr.mm7305a4","article-title":"Comparison of administration of 8-milligram and 4-milligram intranasal naloxone by law enforcement during response to suspected opioid overdose - New York, march 2022-august 2023","volume":"73","author":"Payne","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.neuropharm.2025.110546_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.111062","article-title":"Examination of naloxone dosing patterns for opioid overdose by emergency medical services in Kentucky during increased fentanyl use from 2018 to 2021","volume":"255","author":"Rock","year":"2024","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110546_bib30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40262-024-01355-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of naloxone","volume":"63","author":"Saari","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.neuropharm.2025.110546_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejphar.2018.08.004","article-title":"On the front lines of the opioid epidemic: rescue by naloxone","volume":"835","author":"Skolnick","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110546_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108019","article-title":"Treatment of overdose in the synthetic opioid era","volume":"233","author":"Skolnick","year":"2022","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110546_bib33","article-title":"Synthetic opioids have disrupted conventional wisdom for treating opioid overdose","volume":"12","author":"Skolnick","year":"2024","journal-title":"Drug Alcohol. Depend. Rep."},{"issue":"14","key":"10.1016\/j.neuropharm.2025.110546_bib34","doi-asserted-by":"crossref","first-page":"382","DOI":"10.15585\/mmwr.mm6614a2","article-title":"Characteristics of fentanyl overdose - Massachusetts, 2014-2016","volume":"66","author":"Somerville","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110546_bib35","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/bja\/54.10.1087","article-title":"Plasma fentanyl concentrations and the occurrence of respiratory depression in volunteers","volume":"54","author":"Stoeckel","year":"1982","journal-title":"Br. J. Anaesth."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110546_bib36","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.51839","article-title":"Intranasal naloxone repeat dosing strategies and fentanyl overdose: a simulation-based randomized clinical trial","volume":"7","author":"Strauss","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.neuropharm.2025.110546_bib37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugalcdep.2016.11.033","article-title":"A review: fentanyl and non-pharmaceutical fentanyls","volume":"171","author":"Suzuki","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2025.110546_bib38","article-title":"Detection of illegally manufactured fentanyls and carfentanil in drug overdose deaths\u2014United States, 2021\u20132024","volume":"73","author":"Tanz","year":"2024","journal-title":"MMWR. Morb. Mortal. Weekly Rep."},{"key":"10.1016\/j.neuropharm.2025.110546_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/26331055241247156","article-title":"Collateral damage: neurological correlates of non-fatal overdose in the era of fentanyl-xylazine","volume":"19","author":"Todaro","year":"2024","journal-title":"Neuroscience. Insights."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110546_bib40","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1021\/acschemneuro.3c00750","article-title":"In vitro functional profiling of fentanyl and nitazene analogs at the \u03bc-opioid receptor reveals high efficacy for Gi protein signaling","volume":"15","author":"Tsai","year":"2024","journal-title":"ACS Chem. Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110546_bib41","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1021\/acschemneuro.1c00037","article-title":"DARK classics in chemical neuroscience: etonitazene and related benzimidazoles","volume":"12","author":"Ujv\u00e1ry","year":"2021","journal-title":"ACS Chem. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110546_bib43","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/ALN.0000000000004622","article-title":"Opioid overdose: limitations in naloxone reversal of respiratory depression and prevention of cardiac arrest","volume":"139","author":"van Lemmen","year":"2023","journal-title":"Anesthesiology."},{"key":"10.1016\/j.neuropharm.2025.110546_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.109939","article-title":"Comparative neuropharmacology of structurally distinct non-fentanyl opioids that are appearing on recreational drug markets worldwide","volume":"249","author":"Vandeputte","year":"2023","journal-title":"Drug Alcohol Depend."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110546_bib45","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/acschemneuro.1c00064","article-title":"Synthesis, chemical characterization, and \u03bc-opioid receptor activity assessment of the emerging group of \u201cnitazene\u201d 2-benzylbenzimidazole synthetic opioids","volume":"12","author":"Vandeputte","year":"2021","journal-title":"ACS Chem. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110546_bib46","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1097\/TA.0000000000000400","article-title":"Continuous noninvasive respiratory volume monitoring for the identification of patients at risk for opioid-induced respiratory depression and obstructive breathing patterns","volume":"77","author":"Voscopoulos","year":"2014","journal-title":"J. Trauma Acute Care Surg."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110546_bib47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jat\/bkab117","article-title":"A forward-thinking approach to addressing the new synthetic opioid 2-benzylbenzimidazole nitazene analogs by liquid chromatography\u2013tandem quadrupole mass spectrometry (LC\u2013QQQ-MS)","volume":"46","author":"Walton","year":"2022","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2025.110546_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2023.111775","article-title":"Non-fentanyl new synthetic opioids\u2013An update","author":"Zawilska","year":"2023","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.neuropharm.2025.110546_bib49","author":"Zibbell"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825002527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825002527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T09:24:42Z","timestamp":1779614682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825002527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":47,"alternative-id":["S0028390825002527"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110546","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversal of a synthetic opioid overdose: Insights from a validated translational model","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110546","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110546"}}